Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Atara Biotherapeutics Inc ATRA

Healthcare Biotechnology
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ATRA)

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Business Wire 4 days ago

Atara Biotherapeutics Provides a Business Update

Business Wire 12 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 16, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 14, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 10, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 8, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 7, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

ACCESS Newswire February 6, 2026
View More News ››

Opinion & Analysis (NDAQ:ATRA)

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Streetwise Reports May 28, 2020
View More Opinion ››

Bullboard Posts (NDAQ:ATRA)

Sell buddy sell.Wow.

Otherwise LOSE -O your money big-time with this stock today anyway
coolfooldumbguy - January 12, 2026

Atara Biotherapeutics: Pioneering T-cell Immunotherapy for C

Looks like ATRA is making some serious moves in the T-cell immunotherapy space. Ebvallo getting approved in Europe is huge - first...
MikeTester - January 24, 2025

ATRA....still moving higher post P.O

Now $10.64 You just never know what those Maggots are up to.....too many tricks up their sleeves They will always win.....you will...
Iseneschal - September 5, 2024

ATRA.....now up over $2/sh

go figure....skating !
Iseneschal - September 4, 2024

ATRA......P.O NR from yesterdays close....and it's still up?

  Atara Biotherapeutics Announces $36 Million Registered Direct Offering   2024-09-03 13:16 ET - News Release   ...
Iseneschal - September 4, 2024

RE:ATRA.....recent RS climbing "The Wall"

Wortha repeat....Hell ya !!!!! $14 HOLLA !!!!! On a NR this a.m!!!! Atara Biotherapeutics Announces U.S. FDA Acceptance and...
Iseneschal - July 17, 2024
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »

Podcasts